COCP vs AGEN vs ABUS vs RDVT vs RLAY

For growth investors, Arbutus Biopharma Corporation (ABUS) is the stronger pick with 128.

2% revenue growth year-over-year, versus 10. 4% for Agenus Inc. (AGEN). Red Violet, Inc. (RDVT) offers the better valuation at 53. 9x trailing P/E (36. 5x forward), making it the more compelling value choice. Analysts rate Agenus Inc. (AGEN) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Agenus Inc.

is actually cheaper at 1. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Red Violet, Inc.

(RDVT) delivered a total return of +155. 9%, compared to -93. 9% for Agenus Inc. (AGEN). Over 10 years, the gap is even starker: RDVT returned +6. 4% versus COCP's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Red Violet, Inc.

(RDVT) is the lower-risk stock at 1. 17β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 133% more volatile than RDVT relative to the S&P 500. On balance sheet safety, Arbutus Biopharma Corporation (ABUS) carries a lower debt/equity ratio of 1% versus 19% for Cocrystal Pharma, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arbutus Biopharma Corporation (ABUS) is pulling ahead at 128.

2% versus 10. 4% for Agenus Inc. (AGEN). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to 31. 8% for Relay Therapeutics, Inc.. Over a 3-year CAGR, RLAY leads at 123. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Red Violet, Inc.

(RDVT) is the more profitable company, earning 14. 6% net margin versus -1800. 6% for Relay Therapeutics, Inc. — meaning it keeps 14. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RDVT leads at 14. 6% versus -1971. 6% for RLAY. At the gross margin level — before operating expenses — AGEN leads at 90. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Agenus Inc.

(AGEN) trades at 1. 8x forward P/E versus 36. 5x for Red Violet, Inc. — 34. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AGEN: 95. 5% to $7. 33.

In this comparison, RDVT (0.

6% yield) pays a dividend. COCP, AGEN, ABUS, RLAY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Red Violet, Inc.

(RDVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 17), 0. 6% yield). Agenus Inc. (AGEN) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RDVT: +6. 4%, AGEN: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (COCP (Healthcare) and AGEN (Healthcare) and ABUS (Healthcare) and RDVT (Technology) and RLAY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: COCP is a small-cap quality compounder stock; AGEN is a small-cap quality compounder stock; ABUS is a small-cap high-growth stock; RDVT is a small-cap high-growth stock; RLAY is a small-cap high-growth stock. RDVT pays a dividend while COCP, AGEN, ABUS, RLAY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.